Mpox (monkeypox) vaccine triggers equally strong immune response in smaller than usual doses and in people with or without HIV
Delivering the two-dose mpox vaccine, called JYNNEOS, in smaller than the usual FDA-approved doses, and by injection between layers of the skin rather than by the standard route under the skin, produced a detectable immune response, a new study shows. This also occurred regardless of whether people were living with or without HIV.
Led by researchers at NYU Grossman School of Medicine, the study showed no significant difference in the strength of the immune response (as gauged by the amount of detectable IgG antibodies, immune proteins that help kill the mpox virus) between most of those who received their vaccine injections in small doses ...












